Journal
CANCERS
Volume 13, Issue 20, Pages -Publisher
MDPI
DOI: 10.3390/cancers13205139
Keywords
familial pancreatic cancer; induced pluripotent stem cells; pancreatic organoids; CDKN2A
Categories
Funding
- Deutsche Forschungsgemeinschaft (DFG) [KL 2544/7-1, KL 2544/6-1, GRK 2254/1, K.L. 2544/1-1, K.L. 2544/1-2, K.L. 2544/5-1, PE 3337/1-1]
- Baden-Wurttemberg Foundation ExPoChip
- German Cancer Aid [111879]
- INDIMED-Verbund PancChip
- Else Kroner-Fresenius-Stiftung
- Bausteinprogramm of Ulm University
- Clinician Scientist Program of Ulm University
Ask authors/readers for more resources
The study provides a hereditary human pancreatic cancer model using patient-specific CDKN2A-mutated pluripotent stem cells to investigate tumor initiation and early development, revealing structural and molecular changes following inducible KRAS(G12D) expression in pancreatic duct-like organoids (PDLOs).
Simple Summary:& nbsp;The mutational landscape of pancreatic ductal adenocarcinoma has been delineated in large clinical studies. Such retrospective characterization, however, is limited to late stages of the disease, and exploring the complexity of carcinogenic routes is in its infancy. Here, we provide an in vitro and in vivo model system to directly investigate human PDAC development after the induction of specific oncogenic insults in a cancer-prone ancestry. We reprogrammed plucked human hair-derived keratinocytes from two siblings harboring a pathogenic CDKN2A variant putatively predisposing for PDAC to induced pluripotent stem cells (iPSCs) and additionally introduced an inducible KRAS(G12D) piggyBac expression cassette. Upon KRAS(G12D) induction in differentiated pancreatic duct-like organoids, structural and molecular changes were observed. After orthotopic transplantation either a high-grade precancer lesion or PDAC-like tumor developed. Hereby, we provide a hereditary human pancreatic cancer model which enables further dissection of tumor initiation and early development starting from patient-specific CDKN2A-mutated pluripotent stem cells. Patient-derived induced pluripotent stem cells (iPSCs) provide a unique platform to study hereditary disorders and predisposition syndromes by resembling germline mutations of affected individuals and by their potential to differentiate into nearly every cell type of the human body. We employed plucked human hair from two siblings with a family history of cancer carrying a pathogenic CDKN2A variant, P16-p.G101W/P14-p.R115L, to generate patient-specific iPSCs in a cancer-prone ancestry for downstream analytics. The differentiation capacity to pancreatic progenitors and to pancreatic duct-like organoids (PDLOs) according to a recently developed protocol remained unaffected. Upon inducible expression of KRAS(G12D) using a piggyBac transposon system in CDKN2A-mutated PDLOs, we revealed structural and molecular changes in vitro, including disturbed polarity and epithelial-to-mesenchymal (EMT) transition. CDKN2A-mutated KRAS(G12D) PDLO xenotransplants formed either a high-grade precancer lesion or a partially dedifferentiated PDAC-like tumor. Intriguingly, P14/P53/P21 and P16/RB cell-cycle checkpoint controls have been only partly overcome in these grafts, thereby still restricting the tumorous growth. Hereby, we provide a model for hereditary human pancreatic cancer that enables dissection of tumor initiation and early development starting from patient-specific CDKN2A-mutated pluripotent stem cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available